Therapeutic Outlook in DLBCL: Evaluating Treatment Sequencing from Front-line to Relapsed Refractory Disease - Episode 9
Real World Perspectives: Outcomes for CAR T-cell Therapy in Relapsed/Refractory DLBCL
A review of real-world outcomes for CAR T-cell therapies in the relapsed/refractory setting from ASH 2024, comparing them to clinical trial results and addressing safety management concerns, toxicities, and prophylactic treatment options in practice.
Video content above is prompted by the following:
Please briefly review real world outcomes of CAR T-cell therapies in RR setting (Lee et al. ASH 2024). How do these results compare to trial results?
- How do you address safety management concerns and toxicities in real world practice? What are prophylactic treatment options?
Related Content:
